Infinimmune
- Biotech or pharma, therapeutic R&D
Infinimmune treats human disease with Complete Human® antibody therapeutics. The company's Anthrobody® platform enables the identification and advancement of truly human monoclonal, single-domain, and multi-specific antibodies with unparalleled efficiency, often identifying therapeutic candidates in under 3 months. Infinimmune has also developed GLIMPSE™, a powerful LLM for antibody engineering trained on our proprietary data.
Infinimmune’s therapeutic pipeline targets autoimmune and inflammatory diseases with a focus on first- and best-in-class opportunities. Our anti-IL-22 and anti-IL-17F mAb programs have development candidates (DCs) selected and are initiating cell line development in June 2025. We have a robust pipeline of antibodies targeting high-value biological targets that combine well with our lead programs to deliver exceptional efficacy and durability for patients suffering from a broad range of autoimmune diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}